Scientists Just Took a Big Step Toward Ending the Opioid Epidemic

A new pain medication appears to be less dangerous than the prescription drugs that are killing thousands—and not addictive.

<a href="http://www.istockphoto.com/photo/oxycontin-bottle-on-shelf-gm578596836-99485787?st=_p_oxycontin">Pureradiancephoto</a>/iStock

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


Scientists are one step closer to designing a drug that relieves pain but doesn’t have the harmful side effects of today’s opioid painkillers.

When the rodents treated with the compound were placed on a hot plate, they appeared to experience as much pain relief as those treated with morphine.

The need is clear: In 2014, 14,000 Americans died from overdoses involving prescription opioids like oxycodone or hydrocodone (known by brand names OxyContin and Vicodin). The death toll from prescription opioid overdoses has roughly quadrupled since 1999. The drugs, prescribed for chronic pain, frequently lead to addiction; as many as one in four people prescribed opioids for long-term pain struggles with addiction, according to the Centers for Disease Control. When ingested in high doses, the drugs slow down breathing and can be fatal.

A team of researchers, whose work was published earlier this month in Nature, designed a compound named PZM21 that is producing promising results. Multiple experiments on mice appear to reduce pain without slowing down breathing or being addictive. When the rodents treated with the compound were placed on a hot plate, for example, they appeared to experience as much pain relief as those treated with morphine. Mice showed no preference between being in a chamber where they received PMZ21 and another where they received a saline solution.

Rather than tweaking an existing drug, as most drugs are created, the research team used a combination of computational modeling and synthetic drug generation to design a compound from scratch that would bind well with the known structure of the brain’s opioid receptors. Doing so was a four-year effort, involving researchers from Stanford University, the University of North Carolina at Chapel Hill, the University of California-San Francisco, and Friedrich-Alexander University in Germany.

Of course, there’s a long way between mice studies and a drug on the market for human use; the authors estimate it will be one to two years until the compound makes its way to the Food and Drug Administration for testing. Still, when it comes to developing a drug that could help mitigate today’s opioid crisis, Aashish Manglik, a Stanford physiologist and the study’s lead author, says he is “cautiously optimistic.”

WE'LL BE BLUNT

It is astonishingly hard keeping a newsroom afloat these days, and we need to raise $253,000 in online donations quickly, by October 7.

The short of it: Last year, we had to cut $1 million from our budget so we could have any chance of breaking even by the time our fiscal year ended in June. And despite a huge rally from so many of you leading up to the deadline, we still came up a bit short on the whole. We can’t let that happen again. We have no wiggle room to begin with, and now we have a hole to dig out of.

Readers also told us to just give it to you straight when we need to ask for your support, and seeing how matter-of-factly explaining our inner workings, our challenges and finances, can bring more of you in has been a real silver lining. So our online membership lead, Brian, lays it all out for you in his personal, insider account (that literally puts his skin in the game!) of how urgent things are right now.

The upshot: Being able to rally $253,000 in donations over these next few weeks is vitally important simply because it is the number that keeps us right on track, helping make sure we don't end up with a bigger gap than can be filled again, helping us avoid any significant (and knowable) cash-flow crunches for now. We used to be more nonchalant about coming up short this time of year, thinking we can make it by the time June rolls around. Not anymore.

Because the in-depth journalism on underreported beats and unique perspectives on the daily news you turn to Mother Jones for is only possible because readers fund us. Corporations and powerful people with deep pockets will never sustain the type of journalism we exist to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we need readers to show up for us big time—again.

Getting just 10 percent of the people who care enough about our work to be reading this blurb to part with a few bucks would be utterly transformative for us, and that's very much what we need to keep charging hard in this financially uncertain, high-stakes year.

If you can right now, please support the journalism you get from Mother Jones with a donation at whatever amount works for you. And please do it now, before you move on to whatever you're about to do next and think maybe you'll get to it later, because every gift matters and we really need to see a strong response if we're going to raise the $253,000 we need in less than three weeks.

payment methods

WE'LL BE BLUNT

It is astonishingly hard keeping a newsroom afloat these days, and we need to raise $253,000 in online donations quickly, by October 7.

The short of it: Last year, we had to cut $1 million from our budget so we could have any chance of breaking even by the time our fiscal year ended in June. And despite a huge rally from so many of you leading up to the deadline, we still came up a bit short on the whole. We can’t let that happen again. We have no wiggle room to begin with, and now we have a hole to dig out of.

Readers also told us to just give it to you straight when we need to ask for your support, and seeing how matter-of-factly explaining our inner workings, our challenges and finances, can bring more of you in has been a real silver lining. So our online membership lead, Brian, lays it all out for you in his personal, insider account (that literally puts his skin in the game!) of how urgent things are right now.

The upshot: Being able to rally $253,000 in donations over these next few weeks is vitally important simply because it is the number that keeps us right on track, helping make sure we don't end up with a bigger gap than can be filled again, helping us avoid any significant (and knowable) cash-flow crunches for now. We used to be more nonchalant about coming up short this time of year, thinking we can make it by the time June rolls around. Not anymore.

Because the in-depth journalism on underreported beats and unique perspectives on the daily news you turn to Mother Jones for is only possible because readers fund us. Corporations and powerful people with deep pockets will never sustain the type of journalism we exist to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we need readers to show up for us big time—again.

Getting just 10 percent of the people who care enough about our work to be reading this blurb to part with a few bucks would be utterly transformative for us, and that's very much what we need to keep charging hard in this financially uncertain, high-stakes year.

If you can right now, please support the journalism you get from Mother Jones with a donation at whatever amount works for you. And please do it now, before you move on to whatever you're about to do next and think maybe you'll get to it later, because every gift matters and we really need to see a strong response if we're going to raise the $253,000 we need in less than three weeks.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate